Canadian Cancer Society logo

Kidney cancer

You are here: 

Survival statistics for kidney cancer

Survival statistics for kidney cancer are very general estimates and must be interpreted very carefully. Because these statistics are based on the experience of groups of people, they cannot be used to predict a particular person’s chances of survival.

There are many different ways to measure and report cancer survival statistics. Your doctor can explain the statistics for kidney cancer and what they mean to you.

Relative survival

Relative survival looks at how likely people with cancer are to survive after their diagnosis compared to people in the general population who do not have cancer, but who share similar characteristics (such as age and sex).

In Canada, a 5-year relative survival statistic is reported for kidney cancer. The 5-year relative survival for kidney cancer is 68%. This means that, on average, people diagnosed with kidney cancer are 68% as likely to live 5 years after their diagnosis as people in the general population.

Survival by stage

Survival varies with each stage of kidney cancer. The following factors can also affect survival for kidney cancer.

  • Generally, the earlier kidney cancer is diagnosed and treated, the better the outcome.
  • Different types of kidney cancer may respond differently to treatment.

There are no specific Canadian statistics available for the different stages of kidney cancer. The following information comes from a variety of sources and may include statistics from other countries.

Kidney cancer survival
Stage5-year relative survival









Questions about survival

Talk to your healthcare team if you have questions about survival for kidney cancer and how it might affect your prognosis.


Woman at market in front of CCS poster This truly is a life-saving program, and we are so grateful to Husky Energy for making it happen.

Read more

Funding lifesaving clinical trials

Illustration of science instruments

The Canadian Cancer Society is funding lifesaving clinical trials that give people with cancer access to the newest types of treatment.

Learn more